Retatrutide (LY3437943) is a 39-amino acid acylated triple incretin receptor agonist targeting GIPR, GLP-1R, and GCGR with balanced receptor potency, widely investigated in energy-expenditure and metabolic-flux research.
Scientific Profile & Research Key Points: Retatrutide
Retatrutide (LY3437943) is a 39-amino acid acylated triple incretin receptor agonist targeting GIPR, GLP-1R, and GCGR with balanced receptor potency, widely investigated in energy-expenditure and metabolic-flux research.
Active Batch Release Specifications (Lot SL-2026-152)
Analytical release verification for current Retatrutide (10 mg) inventory
| Batch Lot # | Release Date | Analytical Method | Purity Spec | Endotoxin (LAL) | Moisture |
|---|---|---|---|---|---|
| SL-2026-152 | 2026-10-28 | RP-HPLC (C18, 214nm) + ESI-MS | ≥99.2% (Single Peak) | <0.5 EU/mg | <2.8% (Karl Fischer) |
Laboratory Solubilization & Storage Protocol
Recommended Solvent / Handling
Sterile 0.9% Bacteriostatic Water or sterile PBS (pH 7.4); swirl gently
Temperature & Stability
Store lyophilized at -20°C; refrigerate reconstituted solution at 2°C–8°C (never freeze solution).
Retatrutide — Technical Questions & Answers
What is the molar concentration when reconstituting Retatrutide (10 mg) in 2.0 mL?
Reconstituting the full 10 mg vial of Retatrutide (MW 4731.33 g/mol) in 2.0 mL of diluent produces a 5.00 mg/mL stock solution — equivalent to approximately 1.06 mM (1,057 µM) gross molarity before Net Peptide Content (NPC) adjustment.
How does Retatrutide's counterion stoichiometry affect assay mass calculations?
Retatrutide (CAS 2381089-83-2, formula C221H342N46O68) is supplied as Acetate lyophilized salt. Because counterions and residual bound water contribute to gross lyophilized weight, quantitative receptor-binding assays should apply batch Net Peptide Content (NPC) or active-ion correction rather than gross cake weight alone.
Which analytical methods verify Retatrutide Lot SL-2026-152 and what pathway does it target?
Lot SL-2026-152 undergoes RP-HPLC (C18, 214nm) + ESI-MS confirming ≥99.2% (Single Peak) and identity against 4731.33 g/mol. In preclinical literature, Retatrutide targets Triple GIP Receptor (GIPR), GLP-1R & Glucagon Receptor (GCGR) Agonist (Coskun T. et al., Cell Metab (2022) — LY3437943 (Retatrutide) triple GIP/GLP-1/glucagon receptor pharmacology (PMID: 35985340)).
Related Scientific Monographs
Peer-reviewed mechanism summaries and analytical protocols
SLU-PP-332: Synthetic Pan-ERR Agonist Chemistry, DMSO Solubility & Mitochondrial Biogenesis
Analytical profile of small-molecule pan-ERR agonist SLU-PP-332 (CAS 303760-60-3): nuclear receptor EC50 selectivity, mitochondrial respiration models, and DMSO stock preparation.
Cagrilintide vs Retatrutide: Amylin/Calcitonin Receptors vs Triple Incretin Agonism
Biochemical comparison of long-acting amylin analogue Cagrilintide (AM833) against triple incretin agonist Retatrutide and dual-pathway Cagrilintide + Semaglutide combinations.
Survodutide vs Mazdutide vs Retatrutide: Dual GLP-1/Glucagon and Triple Agonist Biochemistry
Comparative receptor pharmacology of Survodutide (BI 456906), Mazdutide (IBI362), and Retatrutide (LY3437943): GLP-1R/GCGR/GIPR potency ratios and stability.